Comparative Pharmacokinetics of Antisense Oligonucleotides View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

1996-03-25

AUTHORS

Sudhir Agrawal , Jamal Temsamani

ABSTRACT

Antisense oligonucleotides have attracted special interest as a novel class of therapeutic agents for the treatment of viral infection, cancers, and genetic disorders because of their ablhty to inhibit expression of a disease-associated gene in a sequence-specific manner. Gene expression is inhibited by hybrid ization of the oligonucleotide to sequences in the gene or the messenger RNA (mRNA) target by Watson-Crick base pairing. The first example of specific mhibition of gene expression by an ohgonucleotide was reported by Zamecnik and Stephenson (1), who demonstrated that a short oligonucleotide inhibited Rous sarcoma virus replication in cell culture. Since then, the field has progressed enormously. Numerous studies have demonstrated the ability of antisense oligonucleotides to modulate gene expression (2–4). Accompanying chapters in this volume describe the use of antisense oligonucleotides for vanous disease targets. More... »

PAGES

247-270

Identifiers

URI

http://scigraph.springernature.com/pub.10.1385/0-89603-305-8:247

DOI

http://dx.doi.org/10.1385/0-89603-305-8:247

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1018456615

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/21359727


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/03", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Chemical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/0304", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medicinal and Biomolecular Chemistry", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Hybridon, Inc., Worcester, MA", 
          "id": "http://www.grid.ac/institutes/grid.452508.e", 
          "name": [
            "Hybridon, Inc., Worcester, MA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agrawal", 
        "givenName": "Sudhir", 
        "id": "sg:person.01124454740.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124454740.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hybridon, Inc., Worcester, MA", 
          "id": "http://www.grid.ac/institutes/grid.452508.e", 
          "name": [
            "Hybridon, Inc., Worcester, MA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Temsamani", 
        "givenName": "Jamal", 
        "id": "sg:person.0703710210.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703710210.14"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1996-03-25", 
    "datePublishedReg": "1996-03-25", 
    "description": "Antisense oligonucleotides have attracted special interest as a novel class of therapeutic agents for the treatment of viral infection, cancers, and genetic disorders because of their ablhty to inhibit expression of a disease-associated gene in a sequence-specific manner. Gene expression is inhibited by hybrid ization of the oligonucleotide to sequences in the gene or the messenger RNA (mRNA) target by Watson-Crick base pairing. The first example of specific mhibition of gene expression by an ohgonucleotide was reported by Zamecnik and Stephenson (1), who demonstrated that a short oligonucleotide inhibited Rous sarcoma virus replication in cell culture. Since then, the field has progressed enormously. Numerous studies have demonstrated the ability of antisense oligonucleotides to modulate gene expression (2\u20134). Accompanying chapters in this volume describe the use of antisense oligonucleotides for vanous disease targets.", 
    "genre": "chapter", 
    "id": "sg:pub.10.1385/0-89603-305-8:247", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-0-89603-305-4", 
        "978-1-59259-585-3"
      ], 
      "name": "Antisense Therapeutics", 
      "type": "Book"
    }, 
    "keywords": [
      "ability of antisense", 
      "use of antisense", 
      "Rous sarcoma virus replication", 
      "Watson-Crick base pairing", 
      "short oligonucleotides", 
      "sequence-specific manner", 
      "antisense", 
      "disease targets", 
      "oligonucleotide", 
      "RNA targets", 
      "Zamecnik", 
      "therapeutic agents", 
      "base pairing", 
      "cell cultures", 
      "novel class", 
      "gene expression", 
      "first example", 
      "genetic disorders", 
      "disease-associated genes", 
      "special interest", 
      "genes", 
      "field", 
      "agents", 
      "interest", 
      "ability", 
      "virus replication", 
      "chapter", 
      "target", 
      "use", 
      "expression", 
      "sequence", 
      "volume", 
      "messenger RNA targets", 
      "viral infection", 
      "manner", 
      "pairing", 
      "culture", 
      "numerous studies", 
      "example", 
      "class", 
      "replication", 
      "pharmacokinetics", 
      "study", 
      "treatment", 
      "cancer", 
      "infection", 
      "Stephenson", 
      "ization", 
      "disorders", 
      "Comparative pharmacokinetics"
    ], 
    "name": "Comparative Pharmacokinetics of Antisense Oligonucleotides", 
    "pagination": "247-270", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1018456615"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1385/0-89603-305-8:247"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "21359727"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1385/0-89603-305-8:247", 
      "https://app.dimensions.ai/details/publication/pub.1018456615"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_309.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1385/0-89603-305-8:247"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1385/0-89603-305-8:247'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1385/0-89603-305-8:247'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1385/0-89603-305-8:247'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1385/0-89603-305-8:247'


 

This table displays all metadata directly associated to this object as RDF triples.

122 TRIPLES      21 PREDICATES      75 URIs      66 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1385/0-89603-305-8:247 schema:about anzsrc-for:03
2 anzsrc-for:0304
3 anzsrc-for:11
4 anzsrc-for:1115
5 schema:author N262670935e9448f183c054c3adf921ff
6 schema:datePublished 1996-03-25
7 schema:datePublishedReg 1996-03-25
8 schema:description Antisense oligonucleotides have attracted special interest as a novel class of therapeutic agents for the treatment of viral infection, cancers, and genetic disorders because of their ablhty to inhibit expression of a disease-associated gene in a sequence-specific manner. Gene expression is inhibited by hybrid ization of the oligonucleotide to sequences in the gene or the messenger RNA (mRNA) target by Watson-Crick base pairing. The first example of specific mhibition of gene expression by an ohgonucleotide was reported by Zamecnik and Stephenson (1), who demonstrated that a short oligonucleotide inhibited Rous sarcoma virus replication in cell culture. Since then, the field has progressed enormously. Numerous studies have demonstrated the ability of antisense oligonucleotides to modulate gene expression (2–4). Accompanying chapters in this volume describe the use of antisense oligonucleotides for vanous disease targets.
9 schema:genre chapter
10 schema:isAccessibleForFree false
11 schema:isPartOf N537d4db5560246ef80c72acce4f59698
12 schema:keywords Comparative pharmacokinetics
13 RNA targets
14 Rous sarcoma virus replication
15 Stephenson
16 Watson-Crick base pairing
17 Zamecnik
18 ability
19 ability of antisense
20 agents
21 antisense
22 base pairing
23 cancer
24 cell cultures
25 chapter
26 class
27 culture
28 disease targets
29 disease-associated genes
30 disorders
31 example
32 expression
33 field
34 first example
35 gene expression
36 genes
37 genetic disorders
38 infection
39 interest
40 ization
41 manner
42 messenger RNA targets
43 novel class
44 numerous studies
45 oligonucleotide
46 pairing
47 pharmacokinetics
48 replication
49 sequence
50 sequence-specific manner
51 short oligonucleotides
52 special interest
53 study
54 target
55 therapeutic agents
56 treatment
57 use
58 use of antisense
59 viral infection
60 virus replication
61 volume
62 schema:name Comparative Pharmacokinetics of Antisense Oligonucleotides
63 schema:pagination 247-270
64 schema:productId N17313114ccf748c59ce264c083713996
65 N4c1dadab0d144e78adbc3cdad07bcb51
66 Nb308d8aa5cac4e9fa1e5c33d96f34404
67 schema:publisher N0a6c794571434b2e9ae9c6af3d3e7ef7
68 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018456615
69 https://doi.org/10.1385/0-89603-305-8:247
70 schema:sdDatePublished 2022-11-24T21:15
71 schema:sdLicense https://scigraph.springernature.com/explorer/license/
72 schema:sdPublisher N33b38eab397a47998c527da0c3ff70be
73 schema:url https://doi.org/10.1385/0-89603-305-8:247
74 sgo:license sg:explorer/license/
75 sgo:sdDataset chapters
76 rdf:type schema:Chapter
77 N0a6c794571434b2e9ae9c6af3d3e7ef7 schema:name Springer Nature
78 rdf:type schema:Organisation
79 N17313114ccf748c59ce264c083713996 schema:name pubmed_id
80 schema:value 21359727
81 rdf:type schema:PropertyValue
82 N262670935e9448f183c054c3adf921ff rdf:first sg:person.01124454740.04
83 rdf:rest N96eaf5eaf9df49b994ac495ff3da04f8
84 N33b38eab397a47998c527da0c3ff70be schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 N4c1dadab0d144e78adbc3cdad07bcb51 schema:name doi
87 schema:value 10.1385/0-89603-305-8:247
88 rdf:type schema:PropertyValue
89 N537d4db5560246ef80c72acce4f59698 schema:isbn 978-0-89603-305-4
90 978-1-59259-585-3
91 schema:name Antisense Therapeutics
92 rdf:type schema:Book
93 N96eaf5eaf9df49b994ac495ff3da04f8 rdf:first sg:person.0703710210.14
94 rdf:rest rdf:nil
95 Nb308d8aa5cac4e9fa1e5c33d96f34404 schema:name dimensions_id
96 schema:value pub.1018456615
97 rdf:type schema:PropertyValue
98 anzsrc-for:03 schema:inDefinedTermSet anzsrc-for:
99 schema:name Chemical Sciences
100 rdf:type schema:DefinedTerm
101 anzsrc-for:0304 schema:inDefinedTermSet anzsrc-for:
102 schema:name Medicinal and Biomolecular Chemistry
103 rdf:type schema:DefinedTerm
104 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
105 schema:name Medical and Health Sciences
106 rdf:type schema:DefinedTerm
107 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
108 schema:name Pharmacology and Pharmaceutical Sciences
109 rdf:type schema:DefinedTerm
110 sg:person.01124454740.04 schema:affiliation grid-institutes:grid.452508.e
111 schema:familyName Agrawal
112 schema:givenName Sudhir
113 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124454740.04
114 rdf:type schema:Person
115 sg:person.0703710210.14 schema:affiliation grid-institutes:grid.452508.e
116 schema:familyName Temsamani
117 schema:givenName Jamal
118 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0703710210.14
119 rdf:type schema:Person
120 grid-institutes:grid.452508.e schema:alternateName Hybridon, Inc., Worcester, MA
121 schema:name Hybridon, Inc., Worcester, MA
122 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...